Kahn Swick & Foti continues its investigation into Humacyte’s officers and directors, raising governance concerns
Executive summary: Kahn Swick & Foti, LLC confirmed it is continuing its investigation into the officers and directors of Humacyte, Inc. An active probe by a prominent law firm signals potential legal and regulatory exposure for Humacyte, which could impact investor confidence and stock performance.
Who is involved: Charles C. Foti Jr. (partner at Kahn Swick & Foti), Humacyte’s officers and directors, and the law firm Kahn Swick & Foti.
Likely next: The investigation may lead to a formal regulatory request, a shareholder lawsuit, or a public resolution if no wrongdoing is found.
Former Louisiana Attorney General Charles C. Foti Jr. announced that the law firm Kahn Swick & Foti is maintaining its probe into Humacyte Inc.’s leadership. The statement, issued via PR Newswire, offers no new details about alleged misconduct but confirms the inquiry remains active. Such ongoing investigations often precede potential regulatory actions or shareholder lawsuits, which could affect the company’s reputation and valuation.
Timeline
- — Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA (PR Newswire)
- — Humacyte (HUMA) Q2 2026 Earnings Call Transcript (Yahoo Finance)
Analysis — what this means
Sectors affected
- biotechnology
Historical parallels
- Humacyte Q2 2026 earnings call on August 19, 2026